Citation

Grunze H, Schlösser S, Walden J. World J. Biol. Psychiatry 2000; 1(3): 129-136.

Copyright

(Copyright © 2000, World Federation of the Societies of Biological Psychiatry, Publisher Informa - Taylor and Francis Group)

DOI

10.3109/15622970009150580

PMID

12607221

Abstract

In contrast to mania, bipolar depression is usually characterised by longer-lasting episodes and a higher incidence of treatment refractoriness. Additionally, the risks of antidepressive standard treatment regimens are increasingly recognised, especially the risk of a switch into mania or induction of a rapid cycling course. Mood stabilisers, e.g. lithium, and some anticonvulsants, appear to have at least some antidepressant efficacy, which, however, may not be sufficient for treating severe depression. Currently, their use as a monotherapy of mild depression and at the start as a co-medication to antidepressants in severe depression is under consideration. The potential usefulness and risks of currently applied antidepressive treatment strategies as well as potential future developments will be reviewed in this article. At this stage, at least in severe depression, the use of true antidepressants still appears to be mandatory, especially because of the risk of suicide. However, initial combination with a mood stabiliser can be recommended. The treatment of depressive episodes only responsive to ECT should include combination with a mood stabiliser, in this case lithium, right from the start. In patients with lithium refractoriness, mood stabilising anticonvulsants should be initiated directly after the end of the ECT cycle. In order to reach sufficient plasma levels and thus reduce the risk of a switch, a loading therapy is recommended.

Language: en

Keywords

Algorithms; Antidepressive Agents, Tricyclic; Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; Humans; Monoamine Oxidase Inhibitors; Selective Serotonin Reuptake Inhibitors